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αKlotho (Klotho), a type I transmembrane protein and a coreceptor for Fibroblast growth 
factor-23, was initially thought to be expressed only in a limited number of tissues, most 
importantly the kidney, parathyroid gland and choroid plexus. Emerging data may suggest a 
more ubiquitous Klotho expression pattern which has prompted reevaluation of the restricted 
Klotho paradigm. Herein we systematically review the evidence for Klotho expression in 
various tissues and cell types in humans and other mammals, and discuss potential reasons 
behind existing conflicting data. Based on current literature and tissue expression atlases, we 
propose a classification of tissues into high, intermediate and low/absent Klotho expression. 
The functional relevance of Klotho in organs with low expression levels remain uncertain and 
there is currently limited data on a role for membrane-bound Klotho outside the kidney. 
Finally, we review the evidence for the tissue source of soluble Klotho, and conclude that the 















αKlotho (hereafter referred to as Klotho) is a 130 kDa type I membrane-bound protein 
containing two large extracellular domains (KL1 and KL2) with a short single-pass 
transmembrane and a short intracellular domain in its C terminus[1]. On the cell surface 
Klotho forms dimeric complexes with Fibroblast Growth Factor Receptors (FGFRs) that 
function as high-affinity receptors for Fibroblast Growth Factor 23 (FGF23)[2,3]. Klotho is 
also released from the cell membrane by proteolytic cleavage, a process mediated by the 
alpha-secretases ADAM10 and 17[4]. A first cut near the cell membrane (alpha-cut) produces 
a 130 kDa circulating protein, and a second cut (beta-cut) between the KL1 and KL2 domains 
produces two smaller proteins with molecular sizes of approximately 60-70 kDa[5]. In 
addition, a truncated Klotho variant containing only the KL1 domain may be produced 
through alternative splicing, although the physiological relevance of this splicing variant is 
unclear[6]. Both the full-length and the shorter forms of soluble Klotho are hormones, with 
distinct but overlapping effects. The detailed functions of the membrane-bound and soluble 
forms of Klotho are discussed in detail elsewhere in this issue. 
 
The reigning paradigm is that Klotho expression is confined to a small number of tissues, 
most importantly the renal tubules, parathyroid glands and choroid plexus; an expression 
pattern determined by epigenetic regulation[1,7]. Although controversies exist, the kidney is 
commonly assumed to be the principal tissue source of circulating Klotho given that it is the 
largest organ that expresses Klotho at high levels. The aim of this paper is to systematically 
review available data on tissue expression of Klotho, primarily in rodents and humans, and 
address the discrepancies found in the literature. Additionally, we will discuss the tissue 














Discovery of Klotho 
In the original study identifying the mouse Kl gene (encoding for Klotho protein), high 
mRNA levels were reported in kidney, brain and pituitary gland, and lower levels in placenta, 
skeletal muscle, urinary bladder, aorta, pancreas, testis, ovary, colon, and thyroid gland[1]. No 
expression was detected in lung, liver, spleen and a number of other tissues. Shortly 
thereafter, the human KL gene was identified, demonstrating over 80% homology to its mouse 
ortholog[6]. Similar to in mice, gene expression was high in kidney and also in placenta, and 
lower expression was seen in brain, prostate, and small intestine. To this point the expression 
pattern of Klotho had been characterized solely by RNA-based methods. In 2000 the first 
monoclonal antibodies specifically detecting mouse and human Klotho were established, 
allowing investigation of protein expression[8]. Subsequent studies demonstrated that Klotho 
mRNA and protein expression largely overlapped, albeit protein expression in tissues with 
low gene expression could not be validated with immunostaining techniques. In 2004, a novel 
mouse strain with a reporter gene expressed under the Kl promoter was developed, permitting 
precise investigation of Klotho localization during embryonic development and in adult 
mice[9]. Analyses of this model led the authors to conclude that Klotho was exclusively 
expressed in the distal tubules of the kidney, parathyroid gland, sinoatrial node and choroid 
plexus. Over the next years, Klotho expression was reported in additional tissues that were not 
included in the initial screens, such as the inner ear[10], bone-forming cells[11], breast 
tissue[12], and monocytes[13]. More recent studies have provided conflicting data on Klotho 
in the arterial wall [14-16] and proximal tubule[17,18]. Also, a study from 2015 by Lim et al. 
using mass spectroscopy and immunohistochemistry reports widespread expression of Klotho 















Klotho in tissue atlases 
To get an unbiased and systematic overview of Klotho expression in different tissues, we 
compiled data from publicly available RNA-Seq and mass spectrometry databases. RNA-Seq 
data of human tissues from four databases (The FANTOM5 project, The Human Protein 
Atlas, The GTEx Consortium and Illumina Body Map. Data available at 
http://www.ebi.ac.uk/gxa/home) demonstrated high Klotho expression in kidney (normalized 
to 100%), followed by placenta, lung, pancreas, breast and adipose tissue (10-25% of that for 
kidney)(Figure 1A). One database contained data for parathyroid gland, which compared to 
the kidney had approximately 2.5 fold higher expression of Klotho. Expression was low but 
detectable (<10%) in all other examined tissues except for liver. Importantly, none of the 
databases contained expression data for sinoatrial node or choroid plexus. To exclude 
unspecific background expression, we compared the expression with that of SLC34A1 
(NPT2A), a known kidney-specific gene. Indeed, expression of SLC34A1 was almost 
completely confined to the kidney in all four databases (Supplemental Figure 1). For protein 
expression, mass spectrometry data from The Human Proteome Map showed strong 
expression in kidney, and no detectable expression in any of the other investigated tissues, 
including placenta, brain, and prostate (Figure 1B). For mouse tissues we examined three 
RNA-Seq databases (The FANTOM5 project, Blencove et al. and Kaessman et al. Data 
available at http://www.ebi.ac.uk/gxa/home) showing high expression in kidney, low 
expression in brain and cerebellum, and no expression in heart, liver, skeletal muscle, and 
testis (Figure 1C). Of note, none of the RNA-Seq databases differentiate between expression 















Based on the current literature and publicly available gene and protein atlases, we suggest a 
classification into three categories; tissues with 1) high Klotho expression: kidney, 
parathyroid gland, choroid plexus, and sinoatrial node; 2) intermediate-low Klotho 
expression: brain, eye, inner ear, endocrine system, lung, part of the gastrointestinal and 
genitourinary tracts, and placenta; and 3) low-absent Klotho expression; bone, cartilage, skin, 
adipose tissue, liver, spleen, heart, blood and immune cells, and part of the gastrointestinal 
and genitourinary tracts. Klotho expression in arteries is discussed in a separate section due to 
the current controversies in the field. The detailed evidence for Klotho expression in these 
various tissues is discussed in the following sections and summarized in Table 1.  
 
Tissues with high Klotho expression 
Kidney 
In both humans and rodents, the kidney is consistently the organ with the highest mRNA and 
protein levels of Klotho. Initially, Klotho was reported to be exclusively expressed in the 
distal tubules[1]. This was paradoxical given Klotho’s role as a permissive co-receptor for 
FGF23, the chief function of which is to regulate phosphate reabsorption and vitamin D 
metabolism in the proximal tubule. Nevertheless, studies examining the initial response to 
FGF23 injections corroborated this observation, with activation of the MAPK pathway only in 
distal tubules[20]. To explain the effects by FGF23 on phosphate and vitamin D metabolism 
in the proximal tubule, a putative paracrine interplay between the proximal and distal tubule 
was proposed. This theory was later substantiated by mice with a distal nephron-specific 
deletion of Klotho, which displayed hyperphosphatemia and elevated FGF23 levels[21]. By 
contrast, Hu et al. showed expression of Klotho transcripts in microdissected proximal tubules 














immunoelectron microscopy, they further report Klotho protein in the basolateral membrane 
and the apical brush border, as well as the cytoplasm of the proximal tubule. Similarly, 
Andrukhova et al. showed Klotho mRNA and protein expression in microdissected mouse 
proximal tubular segments, and also report that FGF23 directly targets the proximal tubule 
through activation of the ERK1/2-SGK1 pathway[18]. More recently, it was reported that 
Klotho is expressed also by podocytes and ameliorates proteinuria by targeting TRPC6 
channels[22]. Finally, Klotho has been reported not to be expressed in mesangial cells[7]. 
 
To gain a more detailed understanding of Klotho expression in the different tubular segments 
and in podocytes, we gathered data from a recently published RNA-Seq dataset on segment-
specific gene expression in rat[23]. Klotho expression in the S2 segment of the proximal 
tubule was around 30% of that in the distal tubule, supporting the concept of lower but 
distinct expression of Klotho in the proximal tubule (Figure 2A). Of note, its expression in 
microdissected glomeruli was low or undetectable (0-4% relative to distal tubule). Next, we 
employed a commercial in situ hybridization technique called RNAScope to determine the 
expression pattern in mouse and human kidney sections. In mouse, probes were targeted to 
nucleotides 879 – 1844, and in human 797 – 1768, thus targeting both the KL1 and KL2 
domains. Mouse kidney displayed an abundant number of transcripts in distal tubules, and a 
lower but distinctly positive signal in cortical proximal tubules (Figure 2B). The straight S3 
segments of the outer medulla were also positive but at a markedly lower level, whereas the 
collecting ducts were negative. Importantly, we could not validate expression of Klotho in 
intrarenal arteries (Figure 2B, insert). Samples from healthy parts of nephrectomized human 
kidneys stained in a similar way (Figure 2C). Positive staining was seen in some glomeruli, 
although most were negative. No distinct positive staining was found in human intrarenal 














similar expression pattern as for in situ hybridization (Figure 2D). High resolution images of 
mouse and human kidney sections co-stained for Klotho and LTL can be found in 
Supplemental data (Supplemental Figure 2A and B). 
 
To shed further light on Klotho’s role in the proximal tubule, we recently generated three 
different strains of proximal tubule-specific Klotho knockout mice[24]. All three strains had 
reduced urinary phosphate excretion and increased abundance of Npt2a protein in the brush 
border of the proximal tubule, but remained normophosphatemic under unchallenged 
conditions. Effects on vitamin D appeared strain-specific, but were overall modest. These data 
indicate a distinct but functionally limited role for Klotho in the proximal tubule. FGF23-
Klotho signalling in the kidney is discussed more extensively elsewhere in this issue. 
 
Parathyroid gland 
Klotho expression in parathyroid gland was reported already in 2004[9], but it took until 2007 
before it was examined in detail[25,26]. Using primary isolated bovine parathyroid cells, we 
reported that parathyroid cells are a target for FGF23 signalling, and that FGF23 directly 
suppresses parathyroid hormone (PTH) synthesis and secretion[26]. These results were 
supported in vivo in a study by Ben-Dov et al. the same year[27]. A number of subsequent 
studies in humans and rodents have shown that parathyroid Klotho is suppressed in both 
primary and secondary hyperparathyroidism, a mechanism at least partly mediated by 
hypermethylation of the promoter region[28-41]. The reduction in Klotho expression was 
initially believed to confer a parathyroid tissue resistance to FGF23 signalling, explaining the 
concurrently high PTH and FGF23 levels observed in both primary and secondary 














deletion that FGF23 is still able to suppress PTH through a Klotho-independent 
mechanism[42]. The exact function(s) of parathyroid Klotho thus remains unclear, and further 
studies are warranted. 
 
Choroid plexus 
Klotho is expressed widely throughout the brain in mouse and rat, with the highest levels in 
the choroid plexus[21,25,43-50]. Expression of Klotho in human choroid plexus has not yet 
been examined. The exact functions of Klotho in choroid plexus are largely unknown but 
presumably entail calcium transport across the blood-brain barrier, and a role as a tissue 
source for soluble Klotho in cerebrospinal fluid (CSF). 
 
Sinoatrial node 
Despite high expression of Klotho in the sinoatrial node in rodents, only a few studies so far 
have examined its expression pattern and function in this tissue[9,51]. In a study by Takeshita 
et al., the authors demonstrate an essential role of Klotho for sinoatrial node function during 
conditions of cardiac stress[9]. Expression of Klotho in human sinoatrial node has not yet 















Tissues with intermediate Klotho expression 
Head and nervous system 
Originally, significant Klotho mRNA levels were found in murine and rat brain [1,52-54] but 
not in human brain[6,55]. Klotho mRNA is detected rather consistently in mouse or rat 
brain[56-62] and in most[63,64], but not all studies[40], at the protein level. Subsequent 
studies uncovered several distinct areas of the brain that express Klotho. Cerebellar Purkinje 
cells were quickly identified as a cell type that expresses Klotho[19,47], whereas other sites 
with reported expression are the hypothalamus, thalamus, striatum, substantia nigra, 
amygdala, cerebellum, cerebral cortex, dentate gyrus, medulla oblongata, optic nerve, corpus 
callosum, and spinal cord[19,61,65-76]. Fon Tacer et al., however, did not detect any Klotho 
expression in the cerebellum, olfactory bulb, brain stem, or spinal cord[65]. Hippocampal 
Klotho expression was also reported by several groups[66,70,71,77-83]. Many investigators 
have used Klotho null mice tissue as control and found that brain Klotho protein and spinal 
cord Klotho mRNA were detectable in wild-type (WT) mice, but not in Klotho null mice, 
attesting to the specificity of their findings[74,76]. Additionally, Klotho expression is 
suppressed in multiple CNS-derived malignancies including glioblastoma, 
oligodendroglioma, and astrocytoma, indicating that Klotho may have tumor suppressor 
functions in primary brain tumors[84]. Finally, brain pericytes have also been reported to 
express Klotho mRNA[85]. 
 
The function of Klotho in brain has gained significant attention. Massó et al. found that 
Klotho expression declined during ageing in mice, most prominently in prefrontal cortex[86]. 














brains during ageing[87,88]. Klotho deficiency in CNS has been implicated in cognitive 
dysfunctions and dementia[72,77]. 
 
Only a few studies have examined Klotho expression in the eye. Klotho was initially not 
detected in mouse eye by qRT-PCR[65], however, Reish et al. reported retinal Klotho 
expression in the ganglion cell layer, inner nuclear layer, and at a lower level in the outer 
nuclear layer, using a polyclonal antibody (AF1819)[89]. This staining pattern was not 
present in Klotho null retina. In a different study a nuclear staining pattern was demonstrated 
for Klotho in the retina[90]. Another study described detectable Klotho transcript and protein 
levels in human retinal pigmented epithelium (RPE) that could be silenced by anti-Klotho 
siRNA[91]. Finally, Jin et al. reported Klotho mRNA and protein expression in lens 
epithelium, which was down-regulated during ageing and cataract formation[92].  
 
The inner ear was also found to be a site of moderately high Klotho expression by RT-PCR 
and Western blotting[10]. Most notably, the stria vascularis (producing endolymph) was 
found to be positive for Klotho protein[10,93]. Speculatively, Klotho may influence 
endolymph composition by modifying activities of various ion channels. The organ of Corti, 
outer and inner hair cells, and to a lesser extent, spiral ganglion cells, all expressed Klotho 

















The anterior pituitary was early pinpointed as a Klotho-expressing tissue[1], which was 
corroborated by later studies[52,57,65,95]. Notably, Growth Hormone (GH)-producing 
adenomas express lower levels of Klotho mRNA than normal pituitary tissue, whereas non-
functional adenomas have higher Klotho expression[96]. Neidert et al. showed that Klotho 
protein was expressed diffusely in adenoma and in lobular fashion in normal pituitary, only 
partially overlapping with GH-positive cells[97]. Speculatively, Klotho may play a role in 
regulation of GH production and/or secretion and this field merits further investigation.  
 
Relatively high amounts of Klotho in the thyroid gland were reported in some studies [1,65] 
although accidental contamination with parathyroid gland tissue has to be considered as a 
potential source or error. Other studies employing RNA-Seq detect no or very little thyroid 
Klotho (a Fragments Per Kilobase Of Exon Per Million Fragments Mapped (FPKM) value of 
1.93, which amounts to roughly 2 transcripts per cell)[52,55]. Follicular thyroid carcinoma 
cells express Klotho in vitro, and Klotho was suggested to inhibit cell proliferation and 
survival[98]. This observation is consistent with a tumour suppressor function of Klotho. In 
the study by Lim et al., Klotho protein is reported in the thyroid gland[19]. By contrast, we 
detected high expression of Klotho in the parathyroid gland but no expression in adjacent 
thyroid gland using IHC and in situ hybridization on normal mouse and human tissue [42] 
(Figure 3A). 
 
Contrasting most other endocrine tissues, the adrenal glands express low or undetectable 
Klotho levels[1,52,65], albeit some studies indicate Klotho expression in human and murine 
adrenal gland, and in phaeochromocytoma cell lines[55,58,99]. Lim et al. localize Klotho 














Klotho expressed in the zona glomerulosa cells in the adrenal cortex was recently suggested 
to inhibit aldosterone synthesis by down-regulating Cyp11b2 expression[100].  
 
Klotho expression in mammary glands was investigated in 2008 by Wolf et al. who found that 
ductal epithelium and other breast cell lines expressed Klotho mRNA and protein (using the 
monoclonal antibody KM2076) and that its expression decreased during carcinogenesis[12]. 
Later reports are in line with these initial findings[7,19,101-106].  
 
Klotho expression is evident in human and murine pancreas [1,6,52,55,57,62,107], although 
sometimes below the detection limit[65]. The islets of the endocrine pancreas appear to be the 
main site of Klotho expression, although one study reported higher expression in the exocrine 
pancreatic ducts[108]. Abramovitz et al. noted that pancreatic islets exhibit low but detectable 
Klotho expression[108], which has been speculated to protect against the development of type 
1 and type 2 diabetes[109-111]. As for other endocrine tissues its expression has been 
reported to be lower in carcinomas compared to in healthy tissue[108,112]. 
 
Respiratory system 
Klotho expression was originally not detected by RNA-based methods in mouse, rat or human 
lung[1,6,52-54,65]. In subsequent analyses, lung tissues of mice and pigs were found to 
express low levels of Klotho[56], around 300-fold lower than in kidney[57,113]. Consistent 
with these findings, Klotho protein was also not detected in lung tissue lysates by several 
groups, using the monoclonal antibody KM2076[40,114]. In contrast, one study identified 














same group also described that airway epithelium produces Klotho[116], a notion that 
previously had been reported by immunohistochemistry and Western blotting[117]. 
Subsequent analyses of pulmonary cells and cell lines indicate that Klotho may indeed be 
expressed at a low level[103,118-122] and immunohistochemical analysis of lung tumor 
samples (small cell lung cancer and large neuroendocrine carcinoma) have provided evidence 
that loss of Klotho expression is associated with lower survival rates[123,124]. 
 
Gastrointestinal tract, (oesophagus, stomach, small and large intestine)  
Esophageal Klotho protein expression has been investigated in one study, in which Klotho 
expression was detected in the esophageal epithelium, and suppressed in carcinoma[125]. 
Additionally, RNA sequencing has provided a rather low FPKM value of 1.45 in 
esophagus[55]. 
 
Klotho expression is not detected in gastric tissue in most studies[1,52,54,65], or at a very low 
levels[57,126], and an RNA-Seq analysis yielded an FPKM value of 1.39[55]. However, 
Izbeki et al. found that WT mice express significantly more gastric Klotho mRNA than 
Klotho null mice, indicating that it may be of relevance[126]. Using immunofluorescence 
they revealed Klotho expression in the epithelium, smooth muscle cells, and enteric neurons, 
although it is unclear what antibody was used. Focusing on gastric epithelium, Xie et al. also 
report some Klotho mRNA and protein expression, and further show that expression was 
decreased in gastric carcinoma cell lines compared to normal gastric epithelial cells[127]. He 
et al. obtained similar results, which is in line with the common finding that Klotho is down-
regulated in cancers[128]. In conclusion, gastric Klotho expression appears to be low but 















The small intestine is not particularly well studied concerning Klotho expression. Early 
studies either showed no[1,52,54] or little Klotho mRNA expression in rats, mice and humans 
[6,53,129]. Later studies in mice largely echo these results, showing no Klotho mRNA in 
whole lysate of small intestine [56], nor in duodenum, jejunum, or ileum [65], or levels 
several hundred-fold below that of the kidney[57]. One report also includes negative 
immunohistochemistry results for Klotho in murine duodenal epithelium [130]. An RNA-Seq 
analysis yielded an FPKM value of 3.01 for small intestine (and 2.74 specifically for 
duodenum and 1.05 for appendix) [55]. Low expression of Klotho in the small intestine is 
supported by data showing that Klotho mRNA levels in WT jejunum and ileum were higher 
than in Klotho null mice [131]. The authors pinpointed Klotho protein expression to mucosal 
epithelial cells, smooth muscle cells, and in deep muscular plexus interstitial cell of Cajal 
(ICC), but not myenteric plexus ICCs or myofibroblasts[131,132]. Finally, using different 
antibodies, an epithelial staining pattern for Klotho was observed in human jejunum and 
ganglionic cell bodies[19]. With multiple studies confirming low expression, it is likely that 
Klotho is indeed expressed by a number of cell types in the small intestine.  
The large intestine appears to express Klotho at levels similar to the small intestine 
[52,54,57,65], with slightly higher expression in some [1,53,56], and slightly lower 
expression in other studies[6,55,131]. Importantly, Asuzu et al., report similar Klotho 
transcript levels in WT and Klotho null mice, indicating that this might be unspecific 
background expression [131]. However, they do detect a similar expression pattern for Klotho 
protein as in the small intestine. Other authors also report Klotho mRNA and protein in colon, 















Genitourinary tract, (testis, ovaries, cervix, Fallopian tube, prostate, urinary bladder, 
placenta) 
Testicular Klotho mRNA expression was identified in mice in by Kuro-o et al.[1], although 
later studies indicated low[6,52,54,56] or even absent gene expression[53,55,58,65]. 
Immunohistochemistal analyses indicate that Klotho protein is expressed in Sertoli cells and 
in elongating spermatids[46,136], as well as in Leydig cells[19].  
 
In the female reproductive system, Klotho mRNA has consistently been found at moderate 
levels in ovaries from mice, rats, and humans[1,6,52-54,56,57,65]. Similar to the testis, 
Klotho protein is expressed in mature germ cells, i.e. mature oocytes, on the membrane and in 
the cytosol[46]. Reduced Klotho expression has been found in many ovarian carcinomas and 
ovarian carcinoma cell lines, again suggesting a potential tumour suppressor role of 
Klotho[102,137]. 
 
In addition to the ovaries, the cervix may also express some Klotho. PCR data indicate that 
Klotho is expressed in cervix and in cervical cell lines[138,139], although some studies were 
negative[7,140]. At the protein level, however, both endocervix and ectocervix appear to 
express Klotho protein[138,140].  
 
The Fallopian tube has been studied very little and only at the protein level. Lojkin et al. 
report Klotho expression in normal Fallopian tube and reduced expression in carcinoma 
originating from the Fallopian tube[102]. Lim et al. show Klotho expression along the 















The prostate was originally thought to be a tissue with moderate Klotho expression as 
Matsumura et al. detected Klotho mRNA in human prostate by Northern blot[6]. This was 
later confirmed using RT-PCR in both normal and carcinomatous prostate cell lines[141,142]. 
Also, RNA-Seq analysis showed relatively high expression of Klotho (10.9 FPKM) in human 
prostate[55]. Lim et al. recently reported that Klotho protein is expressed in human prostate 
epithelium[19]. In contrast, studies of murine prostate could not confirm Klotho 
expression[56,65]. All in all, the prostate is likely to express above average levels of Klotho, 
at least in humans.  
 
The urinary bladder was initially shown to express Klotho mRNA in mice[1]. This finding has 
been backed by additional data in both mice and humans[55,57]. To the best of our 
knowledge, there are no data available on Klotho protein expression in the urinary bladder. 
 
After the kidney, parathyroid and choroid plexus, the placenta is one of the organs reported to 
express the highest levels of Klotho. Klotho mRNA in placenta was originally detected by 
Kuro-o et al.[1] and confirmed by additional studies[6,52,55,139,143,144]. Placental 
expression of Klotho is also detected by in situ hybridization (Figure 3B). At both mRNA and 
















Skeletal muscle was initially shown to express moderate amounts of Klotho mRNA in 
mice[1],  although subsequent data from human, murine, and rat skeletal muscle revealed that 
the expression was very low or absent[6,53,54,56,65]. Of note, data from Murata et al. 
revealed that Klotho mRNA expression was higher in WT mice than in Klotho null mice, 
indicating a specific gene product[149]. More recent analyses show that Klotho mRNA 
indeed is detectable but expressed several hundred-fold below the level of renal 
Klotho[57,58,61,62,113,150]. Recent attempt to detect Klotho protein in skeletal muscle 
yielded negative results[57,151,152]. Notably, a publication from this year reported low levels 
of Klotho mRNA and protein in skeletal muscle, both of which were decreased in a mouse 
model of Duchenne muscular dystrophy[62]. Skeletal muscle may therefore express Klotho at 
a low but detectable level; speculatively, it may be important in maintaining skeletal muscle 















Tissues with low or no Klotho expression 
Connective tissue and skin 
Bone was originally identified as a tissue without Klotho expression[1,65,153]. Subsequent 
studies indicate that murine and porcine cortical bone do expresses Klotho mRNA at levels of 
400 to 1000-fold lower than the renal cortex[113,154]. Similarly, analyses of Klotho 
expression in isolated bone cells have shown that osteoblasts express Klotho at a level of 
around 800-fold below kidney cortex level[154]. In some studies, Klotho expression was 
below detection level[153,155,156], however, Yuan et al. found that Klotho mRNA levels in 
whole bone and isolated osteoblasts were still around 5- to 10-fold higher in WT than in 
Klotho null mice[154]. Klotho protein analysis equally supports a specific albeit low signal in 
bone[157]. Importantly, deletion of Klotho in long bones points to a functional role of Klotho 
in the regulation of FGF23 production and secretion under uremic conditions[11].  
 
Cartilage is a rather unexplored field in Klotho research. Klotho mRNA was shown to be 
expressed in the growth plate and articular cartilage at a level around 300- to 1,000-fold lower 
than in renal cortex in pigs[113]. Kawai et al. also report very low levels of Klotho mRNA in 
both primary chondrocytes and in a chondrogenic cell line during chondrogenesis[95]. At the 
protein level, however, data are discrepant. Raimann et al. yielded positive 
immunohistochemistry results with an unspecified antibody[113], whereas Kawai et al. did 
not detect Klotho with an unspecified antibody and also showed that chondrocytes are not 
responsive to FGF23, suggesting that Klotho is not present as a functional co-receptor[95]. 
Finally, nucleus pulposus cells were reported to express Klotho mRNA and protein (using the 















Adipose tissue is believed to express Klotho mRNA at low levels. One RNA-Seq study 
showed expression at 3.1 FPKM[55], which is in agreement with the low levels detected by 
qRT-PCR in epididymal white adipose tissue[61]. In contrast, qRT-PCR of white and brown 
adipose tissue[65] and RT-PCR of various (inguinal, visceral, subscapular) white adipose 
tissues[58] have yielded negative results in other studies. However, adipose tissue expression 
was substantially higher in RNA-Seq data from The GTEx Consortium and Illumina Body 
Map (Figure 1A). In adipocyte cell lines, Klotho was found to be expressed at very low levels, 
which increased during differentiation[159,160]. Klotho protein was detected using the 
KM2076 antibody and decreased after anti-Klotho siRNA transfection, suggesting that the 
immunoreactivity on Western blot was specific. 
 
Fibroblasts in connective tissue have only occasionally been investigated. While renal 
embryonic fibroblasts were found not to express Klotho by RT-PCR[7] and Klotho mRNA 
expression was very low in synoviocytes[161], a number of studies indicate that skin 
fibroblasts[162], tenocytes[163], mouse embryonic fibroblasts and fibroblast cell 
lines[164,165] express Klotho protein. In these studies, the molecular size of the detected 
protein are highly variable. Liu et al. detect a 64 kDa protein in a fibroblast cell line, De 
Oliveira et al. do not indicate a protein size[164], and Xie et al. detect a 116 kDa 
protein[162,165]. It is yet to be properly determined whether fibroblasts produce 
physiologically relevant amounts of Klotho. 
 
Skin is another tissue that has not received much scrutiny regarding Klotho expression. 
Originally, skin from mice was found to be negative for Klotho by RT-PCR[1,52], a finding 














RNA-Seq study by Fagerberg et al. yielded a FPKM value of 0.59 for skin, which is below 
one transcript per cell[55]. However, in vitro studies paint a different picture. Kim et al. report 
Klotho mRNA and protein expression in human keratinocytes[166] and Liu et al. detect 
Klotho in human primary keratinocytes and in a keratinocyte cell line[167]. One study that 
focuses on melanoma reports that Klotho expression is inversely proportional to malignant 
behavior of melanoma cell lines[168]. Finally, Lim et al. report high expression of Klotho 
protein in the epidermis, hair follicles, sebaceous glands, and cultured keratinocytes, using 
antibodies ab69208 and/or ab181373[19].  
 
Cardiovascular system 
Initial studies reported absence of Klotho in hearts from mice[1,52,54], which was also the 
case in rat[53] and only a very faint Northern blot band was detected in human heart[6]. Only 
one study indicates a faint RT-PCR band representing a low amount of Klotho transcripts in 
mouse heart[58]. Subsequent studies using either qRT-PCR or RT-PCR approaches confirm 
low or absent levels of Klotho in mouse heart[56,57,60,65,169], and cardiac Klotho 
expression was found to be over 10,000-fold lower than renal Klotho expression levels in pig 
hearts[113]. In an RNA-Seq study, the human heart yielded a very low FPKM value of 
1.11[55]. On the protein level, using antibody KM2076, Lau et al. could not detect Klotho 
expression in mouse heart[40]. A recent article reports that there is no detectable Klotho 
mRNA in heart biopsies from deceased pediatric patients[170]. However, Klotho protein was 
detected by Western blot, at the same molecular size as renal Klotho. This leads the authors to 
raise the question whether cardiomyocytes are able to scavenge and absorb soluble Klotho 















Blood and immune system 
Bone marrow has consistently been found to express virtually no Klotho in humans and in 
mice[1,52]. Vadakke Madathil et al. reported that murine bone marrow Klotho levels were 
around 1,000-fold lower than in kidney[171]. Similarly, RNA-Seq analysis of human bone 
marrow yields a negligible FPKM value of 0.11[55], and normal human bone marrow 
samples were found not to express Klotho protein[105]. However, Raimann et al. estimate 
porcine bone marrow Klotho expression to be only around 10-fold lower than in kidney[113], 
which is highly discrepant from the other observations. 
 
The thymus has never received much interest in the Klotho field, even though it involutes in 
Klotho null mice. Thymic Klotho expression has been found to be undetectable in human, 
mouse, and rat samples[1,6,52,53,56,57,65]. It was detected in 4- to 6-weeks-old pigs as 
around 30,000-fold lower than in kidney[113].   
 
Splenic Klotho expression levels have also relatively consistently proven to be negative by 
Northern blotting, RT-PCR, and qRT-PCR in mouse[1,54,56,57,65,65]. In rat spleen, Klotho 
mRNA could be detected at an extremely low level[53], which was also the case in human 
spleen[6]. Quantitative analysis revealed Klotho to be expressed in spleen at a level of around 
10,000-fold below averaged renal expression levels[113,171], further validating the notion 















Lymph node Klotho expression has only been investigated in one large RNA-Seq study, 
yielding a very low FPKM value of 1.1[55]. To our knowledge, lymph vessels and lymphatic 
endothelium have never been studied in this context. 
 
Blood cells have received more scrutiny in recent years. Human peripheral blood 
mononuclear cells (PBMCs) were found not to express Klotho mRNA[6,7], nor were 
platelets[172] or dendritic cells[173], while a number of analyses indicates that Klotho mRNA 
is at least detectable in lymphocytes[174] and in lymphocyte subsets [175,176]. Bacchetta et 
al. show that in PBMCs from 35 different donors, the average Ct value was 21 cycles higher 
than the Ct value of 18S, which equals > 200,000 times lower expression[13]. They do, 
however, detect Klotho protein in PBMCs using immunofluorescence, which is unexpected 
based on their mRNA results. Chronic myeloid leukaemia cells were found not to express 
Klotho mRNA[7] and acute myeloid leukaemia cells were found to express Klotho mRNA 
and protein, but the quantity could not be inferred[177]. Furthermore, macrophages were also 
shown to express Klotho at an indiscernible expression level, which was higher in M1 
macrophages as compared to M0 and M2 macrophages[178]. 
 
Gastrointestinal tract, (salivary glands, liver, gall bladder) 
The salivary glands have not been a major focus in Klotho research and only a few studies 
have assessed Klotho expression. Using RT-PCR, no Klotho mRNA expression was found in 
murine submandibular gland[1,52]. Similarly, RNA-Seq of human salivary gland yielded a 
very low FPKM value of 0.61[55]. Amano et al. used immunohistochemistry and showed that 














sublingual, or submandibular gland in mouse. However, they found Klotho expression on the 
basal side of granular duct cells[136].  
 
The liver, together with adipose tissue, expresses high levels of β-Klotho, an obligate co-
receptor for Fgf15/FGF19[179]. In contrast, the liver is generally regarded as one of the 
organs that are completely devoid of Klotho. But even the topic of hepatic Klotho expression 
is not without conflicting data. A number of studies report negative data for Klotho mRNA in 
murine, rat and human liver[1,6,52-54,56-58,61,65,67]. More sensitive analyses indicate that 
Klotho mRNA is expressed in liver at a level 1,000- to 10,000-fold lower than in 
kidney[113,171], and RNA-Seq analyses yield very low or undetectable levels (Figure 1A and 
[55]). The liver has also repeatedly been found not to express Klotho protein[19,40]. 
However, there are some studies indicating that normal liver tissue and cell lines express 
Klotho mRNA and protein[180,181] and that the levels are decreased in hepatocellular 
carcinoma (HCC) samples or cell lines[182-185], and in steatotic liver tissue[186]. Whether 
low levels of Klotho predict poor outcome in HCC is also a matter of debate[182-185,187]. 
All in all, we conclude that the levels of Klotho in the liver is extremely low, and is unlikely 
to play a major role in physiology.  
 
The gall bladder and biliary epithelium have so far only been examined in one study of mouse 
tissue, in which no expression was found in the bladder by RT-PCR[65], and in one human 
RNA-Seq study, in which an FPKM value of 1.86 was reported[55]. This is slightly higher 















Genitourinary tract, (epididymis, uterus) 
With regards to the epididymis, one qRT-PCR analysis indicates that Klotho is not expressed 
at all[65], whereas another study reports that Klotho is expressed at a level several hundred-
fold lower than the kidney[57]. No Klotho expression could be detected in seminal vesicles, 
preputial gland, and vas deferens in mice[65].   
 
For uterus, only negative data have been reported in mice and in rats[1,52,53,57,65]. RNA-
Seq analysis yielded a FPKM value of 1.39 for human endometrium[55]. Interestingly, Lim et 
al. report distinct positive Klotho protein expression in human endometrium, which stands in 















Expression of Klotho in arteries 
Arterial Klotho expression is a matter of debate and current literature is contradictive. Given 
the link between FGF23 and vascular complications in CKD, it is of principal interest to 
elucidate whether FGF23 modifies structural or functional properties of the vasculature via 
Klotho-dependent mechanisms. In aorta and in other arteries, Klotho mRNA is either not 
detected[40,52,65,188-190] or detected at an extremely low level[1,16,191-199]. This holds 
true also for vascular smooth muscle cells[15,189,196,200-204] and endothelial 
cells[202,205-211] when analyzed separately. However, at the protein level, data are 
conflicting. Many authors do not detect Klotho protein in aorta[15,16,40,188,212], smooth 
muscle cells[15,196,200,201], or endothelial cells[206,211,213] whereas others 
do[14,19,19,165,195,199,199,207-210,214]. It is also uncertain whether arterial Klotho is 
down-regulated in CKD or not[14,41,193,194,196,214,215]. There is also some evidence that 
Klotho expression is induced at sites of vascular calcification[195,197]. 
Another unresolved issue is that the detected protein in vasculature is usually around 115-120 
kDa, which is smaller than the renal 130 kDa protein. Analysis of the renal and vascular 
samples led us to conclude that the full-length membrane-bound Klotho protein is not 
expressed in arterial tissue or smooth muscle cells[15]. The existence of an alternatively 
spliced Klotho variant in vascular tissue cannot be excluded. A functional role of vascular 
Klotho also remains to be proven. In this regard, mice with a specific deletion of Klotho in 
vascular smooth muscle cells did not display any apparent vascular phenotype[16]. 
Furthermore, acute and chronic FGF23 infusions do not elicit the down-stream Klotho 
dependent signaling response observed in kidney, suggesting that the Klotho receptor 
complex is not functionally present[15,16]. Consistent with these findings, FGF23 treatment 














Tissue source of circulating Klotho 
Both the full-length and the shorter forms of soluble Klotho are detected in serum, urine, and 
CSF[43,216]. Since the kidney is the largest organ with high abundance of Klotho, it is also 
likely to be the principal contributor to circulating Klotho. However, little is known about the 
mechanism(s) that regulate cleavage of Klotho, and the tissue source remained undetermined 
until recently. To address this question, we generated whole-nephron Klotho knockout 
mice[21]. This model recapitulated the severe phenotype of systemic Klotho null mice, 
emphasizing the importance of renal Klotho. Importantly, kidneys harvested from whole-
nephron Klotho knockout mice do not secrete soluble Klotho ex vivo, and soluble Klotho is 
markedly reduced in serum in these mice. Thus, we established the kidney as the chief source 
of serum Klotho in mouse.  
Notably, mice with a proximal-tubule specific deletion of Klotho did not have reduced serum 
Klotho level[24]. There might be several reasons for this. First, Klotho expression in the 
proximal tubule is markedly lower than in the distal tubule, and deletion only in the proximal 
tubule might not be sufficient to lower the serum levels. Second, a deletion of Klotho in the 
proximal tubule might trigger a compensatory upregulation in other Klotho-expressing tissues 
that maintain a constant shedding rate of Klotho. Technical limitations in Klotho 
measurements (based on immunoprecipitation and immunoblotting) might also contribute. 
Another potential explanation is that Klotho in the proximal tubule is shed from the apical 
side into urine, and does not contribute to blood levels. 
In a recent paper by Hu et al., the renal production and handling of Klotho was examined in 
greater detail[217]. The authors first measured soluble Klotho in blood collected from the 
infra-renal and supra-renal vena cava, in rats and humans, and demonstrate an infra-to-supra-
renal Klotho ratio greater than one, indicating that Klotho is released from the kidney into 














half within one day, providing further evidence that the kidneys are the main tissue source of 
soluble Klotho. Finally, the renal handling of soluble Klotho was evaluated by injecting rats 
with fluorescently-labelled recombinant Klotho. Clearance of recombinant protein was 
markedly slower in anephric rats, indicating that the kidney actively contributes to the 
clearance of Klotho.  
Except from the aforementioned reports, data on the tissue source of serum Klotho in humans 
are largely lacking. Patients with CKD have markedly decreased tissue level of Klotho in the 
kidney paralleled by reduced serum concentrations[218,219]. However, CKD is associated 
with a global reduction in tissue Klotho expression and therefore the relative organ-specific 
contributions cannot be inferred from this setting[220]. Similarly, a case report of a patient 
with a inactivating mutation in the KL gene and undetectable serum levels of Klotho does not 
permit further dissection of this question[221].  
Both full-length and the truncated forms of soluble Klotho can also be found in CSF[43]. Due 
to the intrinsic properties of the blood-brain-barrier, only small amounts of Klotho can enter 
the CNS from circulation, and a vast majority is instead produced locally in the CNS. 
Although never assessed in detail it is reasonable to assume that soluble Klotho in CSF is 
mainly produced and shed from the choroid plexus. A recent study of Klotho in CSF from 
pediatric patients undergoing lumbar puncture to exclude inflammatory neurological disease 


















Tissue profiling of Klotho expression is at first glance a simple task, yet several conflicting 
data and controversies have emerged as a consequence of its promiscuous low-grade 
expression pattern and different splice variants. In addition, the widespread use of newer 
polyclonal antibodies, with unproven sensitivity and specificity, is likely to precipitate false 
positive as well as false negative results. In this regard, a number of studies employing 
polyclonal antibodies report positive staining for several tissues expressing very low Klotho 
mRNA levels, contrasting the first monoclonal Klotho antibodies (KM2019 and KM2076), 
which generate consistent results when comparing protein and mRNA data. A detailed list of 
the most commonly used anti-Klotho antibodies can be found in Table 1. Furthermore, a 
recent mass spectrometry-based study demonstrated Klotho protein expression in a wide panel 
of human tissues, some which were not previously categorized as ‘Klotho positive’[19]. 
However, this study provides no quantitative data, and detected an amino acid sequence that 
is present also in soluble Klotho, thus preventing conclusions on amounts, form (membrane-
bound or soluble) or tissue source of the detected protein. To enhance data quality and 
homogeneity, it is recommended that studies reporting on Klotho expression should more 
precisely define the specificity of the antibodies used (i.e. a size indicator and positive and 
negative controls should be included in all analyses, preferentially using recombinant protein 
and tissue from Klotho null mice). Second, protein and mRNA expression should be 
adequately quantified and contextualized in all studies presenting positive data, especially for 
‘new’ tissues. Expression should also be differentiated between the full-length and the 
truncated transcripts. Third, the source of the detected protein (i.e. locally expressed or 















Another unresolved issue is that the molecular size and subcellular localization of Klotho 
differ from the expected (i.e. 60-116 kDa instead of 130 kDa, and nuclear instead of 
membrane-bound/cytoplasmic) in some studies. Whether these findings are equally 
attributable to technical limitations remains to be determined. An alternative, and more 
exciting, explanation is the existence of different Klotho protein forms derived from local 
RNA splice variants or structurally modified full-length Klotho. There is however currently 
limited evidence to support such a hypothesis. 
 
We herein propose a classification for Klotho expression in tissues based on current evidence 
for the basal mRNA and protein expression levels: high expression (distal tubules, parathyroid 
gland, sinoatrial node and choroid plexus), intermediate expression (e.g. proximal tubules, 
brain, eye, inner ear, endocrine system, lung, parts of the genitourinary and gastrointestinal 
tracts, and placenta), and low/absent expression (e.g. bone, cartilage, skin, adipose tissue, 
liver, spleen, heart, arteries, blood and immune cells, and parts of the gastrointestinal and 
genitourinary tracts). The expression level of Klotho in different tissues/cell types and the 
level of evidence are summarized in Table 2. A key discriminator of what constitutes a 
relevant Klotho expression signal is in our view determined by the degree of 
signalling/functionality that can be accredited to Klotho in specific cell types. In this regard, 
there are rather limited data on tissues with reported low-grade expression, whereas the 
evidence for organs with high expression such as kidney and parathyroid glands are robust 
and consistent. Nevertheless, as described herein, organs with very low Klotho expression 
might promote Klotho signalling under certain conditions. Further elucidation of relevant 
tissues and associated conditions is therefore important to adequately portray the details of the 















It should also be recognized that the tissue-specific Klotho level (and the significance thereof) 
is likely to vary substantially depending on stimulatory or repressive signals in the systemic or 
cellular environment. For example, Klotho expression in kidney is reduced in acute and 
chronic kidney injury[223,224]; CNS-derived Klotho is diminished in states of cognitive 
decline[72,225]; and suppressed Klotho is frequently observed in tumours of various 
origin[12,108]. All such confounders must be carefully considered when interpreting 
measured Klotho levels. In fact, in addition to strain and species differences, they may 
account for some of the underlying discrepancies found in the literature on this topic. 
 
Recent genetic and experimental data from us and other groups uncovered the kidney as the 
principal source of soluble Klotho[21]. The simple observation that a renal Klotho deletion 
recapitulates the systemic Klotho null mouse phenotype, whereas other targeted tissue Klotho 
deletions reported so far do not elicit any discernable abnormalities[16,42,226], substantiates 










Table 1. Characteristics of commonly used anti-Klotho antibodies. 
Antibody Company 
 
Described in  Clonality Host species Immunogen Validation 
assessment* 








Rat Human KL1 (aa 55-261) Excellent [5,15,17,21,24,42,43,95,114,
160,196,216,217,223,226-
238] 
Best characterized antibody, 
most reliable in most 
applications  
KM2119  [8] Monoclonal 
(IgG2b) 
Rat Human KL2 (aa 801-954) Excellent [9,43,238,239] Known to be specific, but not 
as well-studied as KM2076 
KM2365  [8] Monoclonal (IgG1) Mouse Human KL1 peptide Poor   
Mink1  [43] Monoclonal (IgG1) Mouse Recombinant mouse KL1 Good [43,95]  
KL-115  [48] Monoclonal Rat Human KL1 (aa 55-261) Very good [48]  
KL-234  [48] Monoclonal Rat Human KL1 (aa 51-261) Very good [48]  
Sb106  [219] Monoclonal Synthetic  Very good [219]  
AF1819 R&D Systems  Polyclonal Goat Mouse recombinant Klotho Excellent [50,67,89,240,241] Best suited for mouse studies.  
MAB1819 
(236214) 
R&D Systems  Monoclonal 
(IgG2a) 
Rat Mouse Klotho (aa 23-550 
and 35-982) 
Poor [131]  
SAB350060
4 
Sigma-Aldrich  Polyclonal Rabbit Internal 16 aa peptide, 
human Klotho 





 Polyclonal Goat Internal region, human 
Klotho  






 Polyclonal Goat Internal region, human 
Klotho  







Rat Mouse recombinant Klotho Moderate [242]  
423500 Merck Millipore  Polyclonal Rabbit 17 aa peptide near the C 
terminus, mouse Klotho 
Poor   
Ab75023 Abcam  Polyclonal Rabbit Peptide between aa 150-
250, human KL1 
Poor  No longer available 
Ab69208 Abcam  Polyclonal Rabbit Peptide between aa 800-
900, human KL2 
Poor  No longer available 
Ab181373 
(EPR6856) 
Abcam  Monoclonal (IgG) Rabbit Peptide between aa 400-
500 
Poor   
Ab154163 Abcam  Polyclonal Rabbit Peptide between aa 100-
200, mouse Klotho 
Poor   
KL11-A Alpha 
Diagnostic 
 Polyclonal Rabbit 17 aa peptide, mouse 
recombinant Klotho 
Good [2,243]  
*The current antibody validation status is summarized as:  
 Poor: the antibody has not been validated or studies report highly discrepant findings 
 Moderate:  the antibody plausibly detects Klotho (it produces the staining pattern that specific anti-Klotho antibodies and RNA in situ 
hybridization produce (i.e. staining in renal distal tubules >> proximal tubules, if tested choroid plexus or parathyroid gland positivity) 












 Good: the antibody was also shown to detect purified recombinant or tagged Klotho protein (the staining pattern disappears after pre-
incubation of antibody and recombinant protein, or recombinant protein is detected on Western blot, or tagged Klotho is detected on 
Western blot after (preferably reciprocate) immunoprecipitation; immunoprecipitated proteins are shown to include Klotho using mass 
spectrometry); 
 Very good: the antibody was also shown be specific for native Klotho protein without aspecific detection of other proteins (the staining 
pattern is not present in knockout tissue, and positive immunostaining or a specific band on Western blot emerges only after transfection 
with Klotho plasmid in Klotho-negative cells/tissue or the staining pattern disappears after RNAi for Klotho in Klotho-expressing cells); 














Table 2. Expression of Klotho in different tissues and cell types   
 
Organ system Organ/tissue Specific cell 
type/structure 
Klotho expression Robustness of 
evidence* 
Head and central 
nervous system 
CNS Neurons Intermediate Excellent 
Purkinje cells Intermediate – higher than most 
neurons 
Moderate 
Choroid plexus High Excellent 
Pericytes Low Poor 
Eye Ganglion layer Intermediate Moderate 
Outer nucleated 
layer 
Intermediate – lower than other 
layers 
Moderate 




Lens epithelium Intermediate Moderate 
Ear Stria vascularis Intermediate - high Moderate 
Hair cells Intermediate Moderate 
Organ of Corti  Intermediate Moderate 
Ganglion cells Intermediate Moderate 
Endocrine system Anterior pituitary  Intermediate Good 
Thyroid gland Follicular epithelium Intermediate Poor 
Adrenal gland Medullary cells Low - intermediate Moderate 
Mammary gland Ductal epithelium Intermediate Moderate 
Endocrine 
pancreas 
 Intermediate  Good 
 Parathyroid gland  High Excellent 
Cardiovascular 
system 
Heart SA node High Good 
 Cardiomyocytes Absent or very low Good 
Arteries Smooth muscle 
cells 
Absent or very low Good 
 Endothelial cells Absent or very low Moderate 




Gastrointestinal tract Salivary gland  Absent Poor 
Esophagus  Low - intermediate Poor 
Stomach  Low - intermediate Moderate 
Small intestine Epithelial cells Low - intermediate Moderate 
 Deep muscular 
plexus interstitial 
cells of Cajal 
Low - intermediate Moderate 
 Smooth muscle Low - intermediate Poor 
 Ganglion cells Low - intermediate Poor 
Colon  Low - intermediate Poor 
 Liver  Absent Good 
 Gall bladder  Absent Poor 
 Exocrine 
pancreas 
 Intermediate Good 
Genitourinary tract Kidney Podocytes Low Moderate 
  Proximal tubule 
cells 
Intermediate Excellent 
  Distal convoluted 
tubule cells 
High Excellent 
 Urinary bladder  Low Poor 
 Prostate  Intermediate Moderate 
 Seminal vesicles  Low Poor 
 Epididymis  Absent or very low Poor 
 Testis Elongating 
spermatids 
Intermediate - high Moderate 
  Sertoli cells Intermediate Moderate 
  Leydig cells Intermediate Poor 
 Ovary Oocyte Intermediate - high Moderate 
 Cervix  Intermediate Moderate 
 Fallopian tube  Intermediate Poor 
 Uterus  Low Poor 
 Placenta Trophoblasts Intermediate Moderate 
Musculoskeletal 
system and skin 
Skeletal muscle  Very low Moderate 














 Cartilage Chondrocytes Very low Moderate 
  Nucleus pulposus 
cells 
Low Poor 
 Adipose tissue  Low Poor 
 Fibrous tissue Fibroblasts Low Poor 
 Skin Keratinocytes Low Moderate 
  Melanocytes Low Poor 
Blood and immune 
system 
Bone marrow  Absent or very low Moderate 
 Thymus  Absent or very low Poor 
 Spleen  Absent or very low Poor 
 Lymph nodes  Absent or very low Poor 
 Blood Lymphocytes and 
monocytes 
Low Moderate 
  Dentritic cells Absent or very low Poor 
  Platelets Absent or very low Poor 
  Macrophages Low Poor 
*The robustness of evidence is summarized as  
 Poor: only mRNA or only protein data, not yet independently replicated, lacking controls 
 Moderate: solid mRNA and/or protein data, not yet independently replicated or difficult to 
reconcile with other studies, or lacking controls 
 Good: multiple studies, assessed at both the protein and mRNA levels, use of validated 
antibodies, but some data are conflicting or controls are lacking 
 Excellent: numerous studies, assessed at both the protein and mRNA level using 
independent methods and validated antibodies, important controls have been performed, 
















Figure 1. Expression of Klotho in tissue atlases.  
A) Expression of Klotho in various human tissues from four RNA-Seq databases. Values have 
been normalized to renal expression (100%) for each database. B) Klotho protein expression 
in various tissues from the Human Proteome Map. C) RNA-Seq data for Klotho from three 
databases of mouse tissues. Raw data available at http://www.ebi.ac.uk/gxa/home and 
http://www.humanproteomemap.org/. 
 
Figure 2. Klotho expression in the kidney 
A) Klotho expression in the rat tubule, using data derived from an RNA-Seq study of 
microdissected tubular segments (Ref: [23]). B) Left panel: In situ hybridization for Klotho in 
mouse kidney reveals high expression in distal tubule, high-moderate expression in the 
proximal tubule, and low-absent expression in glomeruli and intra-renal artery. Right panel: 
Fluorescent in situ hybridization for Klotho (red) and co-staining with the proximal tubular 
marker LTL (green). Colours have been inverted for improved visibility. C) Left panel: In situ 
hybridization for Klotho in human kidney. Expression is high in distal tubule, low-
intermediate in proximal tubule, and low-absent in glomeruli and intra-renal artery. Right 
panel: Fluorescent in situ hybridization for Klotho (red) and co-staining with the proximal 
tubular marker LTL (green). Colours have been inverted for improved visibility. D) 
Immunohistochemistry for Klotho in human kidney reveals a nearly identical expression 
pattern as for mRNA. 
 














A) In situ hybridization reveals distinct Klotho expression in normal human parathyroid 
gland, and no detectable expression in adjacent tissue. B) In situ hybridization reveals distinct 
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 High expression of Klotho is restricted to a few tissues, 
most importantly the kidney 
 Emerging evidence suggest low to intermediate Klotho 
expression in a number of tissues 
 The kidney is the principal source of soluble Klotho 
 Use of different Klotho antibodies is a major source of 
discrepancies in the field 
 We propose a classification based on current evidence for 
Klotho RNA and protein levels 
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